• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Exelixis

Exelixis

Exelixis Inc EXEL

Last Price$13.35Day Change (%)-13.76%
Open Price$15.57Day Change ($)-2.13
Day Range12.07–15.5852-Week Range3.55–15.58

As of Wed 9/28/2016 5:14:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data Presentation at the ESMO 2016 Congress

    Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data Presentation at the ESMO 2016 Congress

  2. Exelixis Announces Outcome from First Planned Interim Analysis of the Phase 3 CELESTIAL Trial of Cabozantinib in Patients with Advanced Hepatocellular Carcinoma

    Exelixis Announces Outcome from First Planned Interim Analysis of the Phase 3 CELESTIAL Trial of Cabozantinib in Patients with Advanced Hepatocellular Carcinoma

  3. European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy

    European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy

  4. European Commission Approves Ipsen’s Cabometyx™ (Cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma (RCC) in Adults Following Prior Vascular Endothelial Growth Factor ...

    European Commission Approves Ipsen’s Cabometyx™ (Cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma (RCC) in Adults Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy

  5. Governor Doug Ducey Will Address Arizona’s Life Science Innovation Community at the Peak of Arizona Bioscience Week During the 11th Annual AZBio Awards

    Governor Doug Ducey Will Address Arizona’s Life Science Innovation Community at the Peak of Arizona Bioscience Week During the 11th Annual AZBio Awards

  6. Is This the Year Exelixis Excels?

    The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.

  7. Beware 5-Star Stocks Bearing No Moats

    Lack of competitive advantages may mean these companies aren't the bargains they seem to be.

  8. Don't Bail on Biotech

    We see opportunity as fleeing investors trigger an irrational sell-off.

  9. Pharmaceutical Firms Get the Urge to Merge

    Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.